Skip to main content

Bruce Alan Sullenger, PhD

Joseph W. and Dorothy W. Beard Professor of Experimental Surgery, in the School of Medicine
Professor of Surgery
Associate Professor in Molecular Genetics and Microbiology
Professor of Pharmacology and Cancer Biology
Professor of Neurosurgery
Office: 1079 MSRB II, Box 103035, Durham, NC 27710
Campus Mail: DUMC Box 103035, Durham, NC 27710

The main focus of my translational research laboratory is to develop RNA based therapeutic agents for the potential treatment of a range of diseases. To this end, we have and will continue to take advantage of the fact that RNA is not just a passive carrier of genetic instructions inside of cells during the conversion of information from DNA to RNA to protein. Rather, RNA is an extremely versatile biological macromolecule. Certian RNAs can bind to specific protiens with high affinities, while others can for catalytic centers and perform enzymatic reactions. These facets of RNA coupled with the ease with which RNA can be manipulated in vitro make it a very powerful and unique therapeutic agent whose potential is largely untapped. Durring our endeavors, we plan to work closely with the members of the Molecular Therapeutics program as well as other faculty at the Duke University Medical Center to expedite the development and testing of these therapeutics.

The specific aims of my laboratory are:

1. To isolate and characterize RNA and DNA aptamers which block therapeutically relavent proteins such as those involved in cardiovascular diseases and immune modulation.

2. To develop RNA-based tumor targeting strategies for delivering siRNAs and miRNAs to tumor cells.

3. To reprogram cells using mRNA delivery.

4. To explore novel methods to control inflammation.

Education and Training

  • Ph.D., Cornell University, 1990

Selected Grants

Weight: 
-20

Publications

Frederiksen, J. W., J. Lohrmann, K. M. Bompiani, R. B. S. Smock-Woodruff, R. B. A. Gunaratne, and B. A. Sullenger. “Aptamer inhibition of an exosite of Factor (F)Xa or thrombin synergizes with non-aptamer inhibition of the catalytic site of FXa or thrombin, respectively.” In Journal of Thrombosis and Haemostasis, 11:123–24. WILEY-BLACKWELL, 2013.

Scholars@Duke

Woodruff, R. S., Y. Xu, J. Layzer, W. Wu, M. L. Ogletree, and B. A. Sullenger. “Inhibiting the intrinsic pathway of coagulation with a factor XII-targeting RNA aptamer..” J Thromb Haemost 11, no. 7 (July 2013): 1364–73. https://doi.org/10.1111/jth.12302.

Full Text

Pratico, Elizabeth D., Bruce A. Sullenger, and Smita K. Nair. “Identification and characterization of an agonistic aptamer against the T cell costimulatory receptor, OX40..” Nucleic Acid Ther 23, no. 1 (February 2013): 35–43. https://doi.org/10.1089/nat.2012.0388.

Full Text

Holl, Eda K., Kara L. Shumansky, George Pitoc, Elizabeth Ramsburg, and Bruce A. Sullenger. “Nucleic acid scavenging polymers inhibit extracellular DNA-mediated innate immune activation without inhibiting anti-viral responses..” Plos One 8, no. 7 (2013). https://doi.org/10.1371/journal.pone.0069413.

Full Text

Ray, Partha, Marcus A. Cheek, Mariam L. Sharaf, Na Li, Andrew D. Ellington, Bruce A. Sullenger, Barbara Ramsay Shaw, and Rebekah R. White. “Aptamer-mediated delivery of chemotherapy to pancreatic cancer cells..” Nucleic Acid Ther 22, no. 5 (October 2012): 295–305. https://doi.org/10.1089/nat.2012.0353.

Full Text

Jain, Shashank, George A. Pitoc, Eda K. Holl, Ying Zhang, Luke Borst, Kam W. Leong, Jaewoo Lee, and Bruce A. Sullenger. “Nucleic acid scavengers inhibit thrombosis without increasing bleeding..” Proc Natl Acad Sci U S A 109, no. 32 (August 7, 2012): 12938–43. https://doi.org/10.1073/pnas.1204928109.

Full Text

Bompiani, K. M., R. S. Woodruff, R. C. Becker, S. M. Nimjee, and B. A. Sullenger. “Antidote control of aptamer therapeutics: the road to a safer class of drug agents..” Curr Pharm Biotechnol 13, no. 10 (August 2012): 1924–34. https://doi.org/10.2174/138920112802273137.

Full Text

Rangnekar, Abhijit, Alex M. Zhang, Susan Shiyuan Li, Kristin M. Bompiani, Majken N. Hansen, Kurt V. Gothelf, Bruce A. Sullenger, and Thomas H. LaBean. “Increased anticoagulant activity of thrombin-binding DNA aptamers by nanoscale organization on DNA nanostructures..” Nanomedicine 8, no. 5 (July 2012): 673–81. https://doi.org/10.1016/j.nano.2011.08.011.

Full Text

Kotula, Jonathan W., Elizabeth D. Pratico, Xin Ming, Osamu Nakagawa, Rudolph L. Juliano, and Bruce A. Sullenger. “Aptamer-mediated delivery of splice-switching oligonucleotides to the nuclei of cancer cells..” Nucleic Acid Ther 22, no. 3 (June 2012): 187–95. https://doi.org/10.1089/nat.2012.0347.

Full Text

Bompiani, K. M., D. M. Monroe, F. C. Church, and B. A. Sullenger. “A high affinity, antidote-controllable prothrombin and thrombin-binding RNA aptamer inhibits thrombin generation and thrombin activity..” J Thromb Haemost 10, no. 5 (May 2012): 870–80. https://doi.org/10.1111/j.1538-7836.2012.04679.x.

Full Text

Pages